Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The HERD Study: Previfenon® as Chemoprophylaxis Against COVID-19
NCT04446065Phase 3Withdrawn
- Sponsor
- MELISA Institute
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Previfenon® with Placebo (2 arms). Primary endpoint: Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR. Planned start Sep 2020; status: withdrawn.
02
Drugs
Previfenon
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04446065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446065.